
## **AMENDMENTS TO THE CLAIMS**

1. (Currently Amended) A compound of general formula (I),



any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein Q is  $-CH_2-CH_2$  or  $-CH_2-CH_2-CH_2$ ; one of  $R^1$  and  $R^2$  is  $-CH_2-CH_2-CH_2-R^3$ ,  $-CH_2-CH=CH-R^3$ , or  $-CH_2-C=C-R^3$ ; wherein  $R^3$  is aryl or heteroaryl; which aryl and heteroaryl is optionally substituted with one or more substituents selected from the group consisting of: halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, and alkynyl; and the other of  $R^1$  and  $R^2$  is  $-CO-R^4$ ; wherein  $R^4$  is alkyl, cycloalkyl, cycloalkylalkyl, aryl, or arylalkyl.

2. (Currently Amended) The compound according to claim 1 or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein Q is -CH<sub>2</sub>-CH<sub>2</sub>-.

- 3. (Currently Amended) The compound according to claim 1 or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein Q is -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-.
- 4. (Currently Amended) The compound according to claim 1 or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein one of R<sup>1</sup> and R<sup>2</sup> is -CH<sub>2</sub>-CH=CH-R<sup>3</sup>; wherein R<sup>3</sup> is defined as in claim 1.
- 5. (Currently Amended) The compound according to claim 1 or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein R<sup>4</sup> is alkyl.
- 6. (Currently Amended) The compound according to claim 1 or <u>any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof</u>, wherein Q is -CH<sub>2</sub>-CH<sub>2</sub>- or -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-; one of R<sup>1</sup> and R<sup>2</sup> is -CH<sub>2</sub>-CH=CH-R<sup>3</sup>, or -CH<sub>2</sub>-C≡C-R<sup>3</sup>; wherein R<sup>3</sup> is phenyl; and the other of R<sup>1</sup> and R<sup>2</sup> is -CO-R<sup>4</sup>; wherein R<sup>4</sup> is alkyl.
- 7. (Currently Amended) A compound of claim 1 or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, which is (±)-1-[9-(3-Phenylallyl)-3,9 diaza-bicyclo[4.2.1]non-3-yl]-propan-1-one; (±)-1-[10-(3-Phenylallyl)-3,10-diaza bicyclo[4.3.1]dec-3-yl]-propan-1-one; (±)-1-[3-(3-Phenylallyl)-3,9-diazabicyclo[4.2.1]non-9-yl]-propan-1-one; or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof.
- 8. (Previously Presented) A pharmaceutical composition, comprising a therapeutically effective amount of a compound of claim 1, or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.

Docket No.: 2815-0290PUS1

9. (Previously Presented) A method for treatment or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to modulation of the opioid receptor, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound according to claim 1, or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof; wherein the disease, disorder or condition responsive to modulation of the opioid receptor is pain.

## 10. - 11. (Cancelled)

12. (Previously Presented) The method according to claim 9, wherein said pain is postoperative pain, chronic pain, cancer pain, neuropathic pain or pain during labor and delivery.